MoonLake Immunotherapeutics AG

ACTIVE

Unknown Belgian address 0, Unknown, Belgiumwww.moonlaketx.comPublic11–50 employeesEstablished: 2021-03-01

Part of helix acquisition corp.

Clinical Trials

11 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2021

Overview

Trial Phase Distribution

Phase

Trials

Phase 3

48.0%

Phase 1

32.0%

Phase 2

20.0%

Trial Status Distribution

Active, not recruiting

36.0%

Completed

20.0%

Enrolling By Invitation

8.0%

Recruiting

36.0%

Clinical Trials

Trials sponsored by this organization (25)

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Phase 3

Enrolling By Invitation

interventional

Nov 20251,560 participants

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Enrolling By Invitation

interventional

Jun 2025835 participants

An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

Phase 1

Completed

interventional

Jun 2025120 participants

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

Phase 3

Active, not recruiting

interventional

Dec 202435 participants

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Phase 3

Active, not recruiting

interventional

Oct 2024960 participants

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Phase 3

Recruiting

interventional

Oct 2024600 participants

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Completed

interventional

May 2024422 participants

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Completed

interventional

May 2024418 participants

Page 1 of 4

Approvals

No approval data available

News

No news articles found

Back to Organizations